September 1, 2024
Sustained Drug Delivery Articles
June 1, 2024
Real-world Pearls for iDose TR Implantation
By Savak “Sev” Teymoorian, MD, MBA
June 1, 2024
Positive Phase 2b Results for Bimatoprost-eluting Contact Lens
By Conni Koury, contributing editor
June 1, 2024
Positive Travoprost Implant Data Presented at ASCRS
By Conni Koury, contributing editor
June 1, 2024
Data on IOL-based Delivery of Bimatoprost Presented at ASCRS
By Conni Koury, contributing editor
April 19, 2024
Permanent J-code Assigned for iDose TR
By Jim Gallagher, senior managing editor
March 1, 2024
Biodegradable Latanoprost Implant Promising in Phase 2a
By Conni Koury, contributing editor
March 1, 2024
SpyGlass Pharma's Long-term Bimatoprost Implant Studied in Phase 1/2 Trial
By Conni Koury, contributing editor
March 1, 2024
Travoprost Implant Lowered IOP Better Than Topical PGA Monotherapy
By Conni Koury, contributing editor
March 1, 2024
No Significant ECD Loss Seen With Travoprost Implant
By Conni Koury, contributing editor
March 1, 2024
Surgical Exchange of Travoprost Implant Safe
By Conni Koury, contributing editor
March 1, 2024
At 3 Years IOP Controlled in More Subjects With Travoprost Implant vs Topical Timolol
By Conni Koury, contributing editor
March 1, 2024
Combined Trabecular Microbypass and Goniotomy Effective
By Conni Koury, contributing editor
March 1, 2024
Sustained-delivery Glaucoma Treatments
By Galia Deitz, MD, Cara E. Capitena-Young, MD
March 1, 2024
From the Editor: Glaucoma’s Tipping Point
By Nathan M. Radcliffe, MD
September 1, 2023
FDA Accepts NDA for iDose TR
By Conni Koury, contributing editor
September 1, 2023
Bimatoprost-eluting Contact Lens Validated in Trial
By Conni Koury, contributing editor
September 1, 2023
SpyGlass Completes Financing to Support Drug-delivery Platform Trials
By Conni Koury, contributing editor
June 1, 2023
Celanese to Supply Drug Delivery Platform for Glaukos iDose TR Implant
By Rochelle Nataloni, contributing writer
June 1, 2023
New Research in Smart Contact Lens Diagnosis and Management of Glaucoma
By Rochelle Nataloni, contributing writer
June 1, 2023
Data on the iDose Intracameral Travoprost Sustained-release Implant
By Inder Paul Singh, MD
March 1, 2023
Phase 2b Study of MediPrint Proprietary Drug-Eluting Contact Lens for Glaucoma Initiated
By Conni Koury, contributing editor
March 1, 2023
Six-month Data Presented for SpyGlass Drug-eluting IOL
By Conni Koury, contributing editor
December 1, 2022
SpyGlass Pharma Presents First-in-human Data on IOL-based Drug-delivery Platform
By Conni Koury, contributing editor
December 1, 2022
Phase 3 Study of Glaukos iDose TR Met Primary Efficacy Endpoints
By Conni Koury, contributing editor
September 1, 2022
From the Editor: Five Years of Glaucoma Physician
By Nathan M. Radcliffe, MD
June 1, 2022
Update on Current Surgical Management of Pediatric Glaucoma
By Rebecca F. Neustein, MD, MARLENE R. MOSTER, M.D.
June 1, 2022
Glaukos iDose TR Demonstrates IOP Reduction, Favorable Safety in Phase 2b Study
By Conni Koury, contributing editor
March 1, 2022
Study: Durysta Bimatoprost Implant Effective for OAG, Ocular Hypertension
By Conni Koury, contributing editor
December 1, 2020
Early-stage Sustained-release Implant Uses Latanoprost
By Jerry Helzner, contributing editor
September 1, 2020
Tips and Tricks for Durysta Injection
By E. Randy Craven, MD
June 1, 2020
Graybug Studying Sustained-Release Glaucoma Drug
By Jerry Helzner, contributing editor
June 1, 2020
Ocular Therapeutix: Positive Data on Long-Term Implant
By Jerry Helzner, contributing editor
June 1, 2020
New, Detailed Phase 3 Data on Durysta Implant Presented at ASCRS
By Jerry Helzner, contributing editor
March 6, 2020
FDA Approves Breakthrough Sustained-Release Glaucoma Implant
By Jerry Helzner, contributing editor
March 4, 2020
Second Phase 3 Trial Validates Efficacy of Bimatoprost SR
By Jerry Helzner, contributing editor
March 1, 2020
The Glaucoma Therapy Pipeline
By John R. Samples, MD
Advertisement
Recommendations
Advertisement